Noradrenergic function in obsessive-compulsive disorder: Behavioral and neuroendocrine responses to clonidine and comparison to healthy controls

Eric Hollander, Concetta DeCaria, Anca Nitescu, Thomas Cooper, Bert Stover, Robert Gully, Donald F. Klein, Michael R. Liebowitz

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

To evaluate noradrenergic (NE) function in obsessive-compulsive disorder (OCD), behavioral, phychological, and neuroendocrine responses to the α2-adrenergic agonist clonidine were examined in 18 patients with OCD and 10 healthy subjects. Subjects received single i.v. doses of 2μg/kg of clonidine administered under double-blind, placebo-controlled, random-assignment conditions. Following clonidine, but not following placebo, patients transiently experienced a significant reduction of obsessions and compulsions. Significant drowsiness and a reduction in anxiety were also noted, but the antiobsessional effect appeard independent of the soporific and antianxiety effects. Growth hormone (GH), cortisol, and 3-methoxy-4-hydroxyphenylglycol responses to clonidine did not differentiate patients from healthy controls. Blood pressure and pulse in response to clonidine did not differ between groups. Improvement in OCD symptoms after clonidine significantly correlated with GH response to clonidine, suggesting specific noradrenergic mediation. This finding lends only partial support for a primary defect of noradrenergic function in OCD.

Original languageEnglish (US)
Pages (from-to)161-177
Number of pages17
JournalPsychiatry Research
Volume37
Issue number2
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Obsessive-Compulsive Disorder
Clonidine
Growth Hormone
Placebos
Obsessive Behavior
Adrenergic Agonists
Sleep Stages
Anti-Anxiety Agents
Hydrocortisone
Healthy Volunteers
Anxiety
Blood Pressure

Keywords

  • 3-methoxy-4-hydroxyphenylglycol
  • anxiety disorders
  • clonidine
  • growth hormone
  • norepinephrine
  • Obsessive-compulsive disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Noradrenergic function in obsessive-compulsive disorder : Behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. / Hollander, Eric; DeCaria, Concetta; Nitescu, Anca; Cooper, Thomas; Stover, Bert; Gully, Robert; Klein, Donald F.; Liebowitz, Michael R.

In: Psychiatry Research, Vol. 37, No. 2, 1991, p. 161-177.

Research output: Contribution to journalArticle

Hollander, Eric ; DeCaria, Concetta ; Nitescu, Anca ; Cooper, Thomas ; Stover, Bert ; Gully, Robert ; Klein, Donald F. ; Liebowitz, Michael R. / Noradrenergic function in obsessive-compulsive disorder : Behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. In: Psychiatry Research. 1991 ; Vol. 37, No. 2. pp. 161-177.
@article{53cd0965fdf4433689c8ca5bb17a26f7,
title = "Noradrenergic function in obsessive-compulsive disorder: Behavioral and neuroendocrine responses to clonidine and comparison to healthy controls",
abstract = "To evaluate noradrenergic (NE) function in obsessive-compulsive disorder (OCD), behavioral, phychological, and neuroendocrine responses to the α2-adrenergic agonist clonidine were examined in 18 patients with OCD and 10 healthy subjects. Subjects received single i.v. doses of 2μg/kg of clonidine administered under double-blind, placebo-controlled, random-assignment conditions. Following clonidine, but not following placebo, patients transiently experienced a significant reduction of obsessions and compulsions. Significant drowsiness and a reduction in anxiety were also noted, but the antiobsessional effect appeard independent of the soporific and antianxiety effects. Growth hormone (GH), cortisol, and 3-methoxy-4-hydroxyphenylglycol responses to clonidine did not differentiate patients from healthy controls. Blood pressure and pulse in response to clonidine did not differ between groups. Improvement in OCD symptoms after clonidine significantly correlated with GH response to clonidine, suggesting specific noradrenergic mediation. This finding lends only partial support for a primary defect of noradrenergic function in OCD.",
keywords = "3-methoxy-4-hydroxyphenylglycol, anxiety disorders, clonidine, growth hormone, norepinephrine, Obsessive-compulsive disorder",
author = "Eric Hollander and Concetta DeCaria and Anca Nitescu and Thomas Cooper and Bert Stover and Robert Gully and Klein, {Donald F.} and Liebowitz, {Michael R.}",
year = "1991",
doi = "10.1016/0165-1781(91)90073-X",
language = "English (US)",
volume = "37",
pages = "161--177",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Noradrenergic function in obsessive-compulsive disorder

T2 - Behavioral and neuroendocrine responses to clonidine and comparison to healthy controls

AU - Hollander, Eric

AU - DeCaria, Concetta

AU - Nitescu, Anca

AU - Cooper, Thomas

AU - Stover, Bert

AU - Gully, Robert

AU - Klein, Donald F.

AU - Liebowitz, Michael R.

PY - 1991

Y1 - 1991

N2 - To evaluate noradrenergic (NE) function in obsessive-compulsive disorder (OCD), behavioral, phychological, and neuroendocrine responses to the α2-adrenergic agonist clonidine were examined in 18 patients with OCD and 10 healthy subjects. Subjects received single i.v. doses of 2μg/kg of clonidine administered under double-blind, placebo-controlled, random-assignment conditions. Following clonidine, but not following placebo, patients transiently experienced a significant reduction of obsessions and compulsions. Significant drowsiness and a reduction in anxiety were also noted, but the antiobsessional effect appeard independent of the soporific and antianxiety effects. Growth hormone (GH), cortisol, and 3-methoxy-4-hydroxyphenylglycol responses to clonidine did not differentiate patients from healthy controls. Blood pressure and pulse in response to clonidine did not differ between groups. Improvement in OCD symptoms after clonidine significantly correlated with GH response to clonidine, suggesting specific noradrenergic mediation. This finding lends only partial support for a primary defect of noradrenergic function in OCD.

AB - To evaluate noradrenergic (NE) function in obsessive-compulsive disorder (OCD), behavioral, phychological, and neuroendocrine responses to the α2-adrenergic agonist clonidine were examined in 18 patients with OCD and 10 healthy subjects. Subjects received single i.v. doses of 2μg/kg of clonidine administered under double-blind, placebo-controlled, random-assignment conditions. Following clonidine, but not following placebo, patients transiently experienced a significant reduction of obsessions and compulsions. Significant drowsiness and a reduction in anxiety were also noted, but the antiobsessional effect appeard independent of the soporific and antianxiety effects. Growth hormone (GH), cortisol, and 3-methoxy-4-hydroxyphenylglycol responses to clonidine did not differentiate patients from healthy controls. Blood pressure and pulse in response to clonidine did not differ between groups. Improvement in OCD symptoms after clonidine significantly correlated with GH response to clonidine, suggesting specific noradrenergic mediation. This finding lends only partial support for a primary defect of noradrenergic function in OCD.

KW - 3-methoxy-4-hydroxyphenylglycol

KW - anxiety disorders

KW - clonidine

KW - growth hormone

KW - norepinephrine

KW - Obsessive-compulsive disorder

UR - http://www.scopus.com/inward/record.url?scp=0025806756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025806756&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(91)90073-X

DO - 10.1016/0165-1781(91)90073-X

M3 - Article

C2 - 1876628

AN - SCOPUS:0025806756

VL - 37

SP - 161

EP - 177

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 2

ER -